Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study will determine the safety, tolerability, and pharmacokinetics of a single dose of
GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.